1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
Status:
Completed
Trial end date:
2017-06-30
Target enrollment:
Participant gender:
Summary
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an
optional Open-label Extension to evaluate the efficacy of bremelanotide (BMT), administered
subcutaneously (SC) on an as needed basis for the treatment of HSDD (with or without
decreased arousal) in premenopausal females.